SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

11 Feb 2025 Evaluate
The revenue for the December 2024 quarter is pegged at Rs. 1950.19 millions, about 20.22% up against Rs. 1622.13 millions recorded during the year-ago period.Profit after tax improved marginally to Rs. 152.27  millions for the quarter ended December 2024 from Rs. 150.98 millions of corresponding previous quarter.The company reported a good operating profit of 283.69 millions compared to 235.01 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 1950.19 1622.13 20.22 5571.73 4596.71 21.21 6309.56 5130.83 22.97
Other Income 37.31 31.64 17.92 127.05 90.28 40.73 134.68 99.65 35.15
PBIDT 283.69 235.01 20.71 812.72 651.95 24.66 915.70 702.07 30.43
Interest 14.60 3.05 378.69 30.55 8.27 269.41 11.03 7.86 40.33
PBDT 269.09 231.96 16.01 782.17 643.68 21.52 904.67 694.21 30.32
Depreciation 69.39 33.89 104.75 196.50 99.08 98.32 134.44 123.64 8.74
PBT 199.70 198.07 0.82 585.67 544.60 7.54 770.23 570.57 34.99
TAX 47.43 47.09 0.72 142.03 132.65 7.07 188.79 144.13 30.99
Deferred Tax 8.20 2.39 243.10 5.36 4.42 21.27 15.35 0.63 2336.51
PAT 152.27 150.98 0.85 443.64 411.95 7.69 581.44 426.44 36.35
Equity 104.50 103.99 0.49 104.50 103.99 0.49 103.99 104.63 -0.61
PBIDTM(%) 14.55 14.49 0.41 14.59 14.18 2.84 14.51 13.68 6.06

Windlas Biotech Share Price

871.75 5.60 (0.65%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×